|
|
Home > Business/Finance > Financial Services > Financial Management
Portfolio Management: Best Practice in Optimizing Resource Allocation
|
| Published Date:
June 2001
Published By:
Datamonitor
Page Count:
133
Order Code:
R313-0057
|
|
|
|
EXECUTIVE SUMMARY
Report summary
Introduction
Patient potential for vaccines
Unmet needs in vaccine market
Investors in vaccine market
Indication focus
Future market leaders
R&D opportunities in vaccines
DISEASE OVERVIEW
Vaccine definition
Passive immunization
Active immunization
Respiratory Syncitial Virus (RSV)
Parainfluenza virus (PIV)
Rotavirus
Streptococcus pneumoniae
Neisseria Meningitidis
Influenza
Lyme disease
Helicobacter pylori
Human papillomavirus (HPV)
Varicella zoster virus (VZV)
Cytomegalovirus
Group A staphylococcus (GAS)
Group B streptococcus (GBS)
Chlamydia
Herpes simplex virus (HSV)
Epstein-Barr virus
Diphtheria, tetanus and pertussis
Hemophilus influenza type b
Measles, mumps and rubella (MMR)
Patient potential of vaccines
Childhood vaccinations
Other vaccinations
Classification of pipeline products
Clinical endpoints in disease
Immunogenicity
Efficacy
Surrogate markers
Unmet needs in vaccine market
Lack of alternative delivery techniques
Low efficacy
New disease targets
Poor safety profiles
Refridgerator storage
Manufacturing difficulties and risks
VACCINE PIPELINE ANALYSIS
Pipeline analysis by development strategy
Key vaccine discovery strategies
Key R&D protocol strategies in vaccines
Key drug delivery strategies in vaccines
Key licensing strategies in the vaccine industry
Pipeline analysis by indication
Pipeline analysis by region
Pipeline analysis by company type
Pipeline analysis by individual company
VACCINE ANALYSIS
Respiratory syncytial virus vaccines
AHP's RSV subunit vaccine
Fabre's recombinant RSV vaccine
GSK adjuvant RSV vaccine (SBAS4)
Parainfluenza virus vaccines
Aviron's PIV3 vaccine
Rotavirus
Rotarix
Bovine derived rotavirus
Streptococcus pneumoniae
QUILIMMUNE-P
AHP PnCRM9
11 valent Pneumococcal
Influenza vaccines
FluMist
Aventis' adjumer formulated influenza vaccines
Herpes simplex vaccines
Simplirix and adjuvant
TA-HSV (& DISC HSV)
MMR and VZV
MMR-V (Merck)
GSK's MMR-V
Shingles vaccine
Cytomegalovirus vaccine
Chiron's gBMF59
Human papilloma virus
Cantab TA-HPV
MedImmune's MEDI-501
Merck's Virus-like particles (VLPs)
Neisseria Meningitidis
Components of combination vaccines
Booster vaccine doses
Key phase I development projects
Cell-cultured Fluviral
Aviron's EBV vaccine
Key pre-clinical/research development projects
Vaccine groups for which no marketed vaccine is yet available
Vaccine groups for which a marketed vaccine does currently exist
COMPARATIVE ANALYSIS
Comparitive analysis of vaccines for which no current vaccine is marketed
towards indicated disease
Introduction
Respiratory syncytial virus (RSV)
Current treatment strategies
Current prophylactic strategies
Comparative analysis of developmental RSV vaccines and Synagis
Parainfluenza virus
Current theapeutic strategies
Rotavirus
Current theapeutic strategies
Herpes Simplex virus
Current therapeutic strategies
Comparative analysis of developmental HSV vaccines and acyclovir
Cytomegalovirus
Congenital CMV
Transplant CMV
HIV retinitis
Comparative analysis of developmental CMV vaccine and ganciclovir
Human papillomavirus
Comparative analysis of genital warts vaccine and Aldara cream
Comparative analysis of cervical cancer vaccine and current treatment
Comparitive analysis of vaccines for which marketed vaccine currently exists for
disease indication
Introduction
Influenza
Comparative analysis of developmental influenza vaccines and Fluad
Streptococcus pneumonia
MMR and VZV
FUTURE FOCUS IN VACCINES
Vaccine market drivers
Future trends in populations
Prospective vaccine launches
Launch forecast methodology
Forecast launches in vaccines from 2000 to 2007
Forecast methodology
Predicting market share
Forecasting future growth
Influencing factors
Influenza market forecast
Influenza market sales forecast, 2000-2007
MMR and VZV market forecast
MMRV/VZV market sales forecast, 2000-2007
Streptococcus pneumonia market forecast
Streptococcus pneumonia market sales forecast, 2000-2007
Neisseria meningitidis vaccine market forecast
Meningococcal market sales forecast, 2000-2007
Combination market forecasts
Combination market sales forecasts
Human papillomavirus market forecast
HPV market sales forecasts, 2000-2007
CMV Market forecast
CMV market sales forecasts, 2000-2007
Herpes simplex virus market forecasts
HSV market sales forecasts, 2000-2007
Rotavirus market forecast
Rotavirus vaccine market sales forecasts, 2000-2007
Parainfluenza virus vaccine market forecasts
Parainfluenza virus market sales forecasts
Respiratory syncytial virus vaccine market forecasts
Respiratory syncytial virus market sales forecasts
Long term potential of early phase vaccines
APPENDIX
Research programme methodology
SPRINT databases
Primary Research
Quantification of Data Reliability
Forecasting Methdology
LIST OF TABLES
LIST OF FIGURES
(c) Datamonitor 2000. All Rights Reserved |
Similar Products
• Financial Planners and Investment Advisors
Published Oct 2008 by First Research, Inc.
• Open-End Investment Funds in the US - Industry Risk Rating Report
Published Oct 2008 by IBISWorld
• Financial Planning & Advice in the US - Industry Risk Rating Report
Published Oct 2008 by IBISWorld
• Plimsoll Analysis- Independent Financial Advisors (UK)
Published Oct 2008 by Plimsoll Publishing Ltd.
• Aging Population in the Western World - Investment Opportunities
Published Sep 2008 by Frost & Sullivan
• Financial Planning & Investment Advice in Australia - Industry Risk Rating Report
Published Sep 2008 by IBISWorld
• Financial Advisors' Views of Service
Published Sep 2008 by Datamonitor
• Financial Planning & Investment Advice in Australia - Industry Market Research Report
Published Aug 2008 by IBISWorld
• Annuities - UK
Published Aug 2008 by Mintel International Group Ltd.
• Munder Capital Management
Published Jul 2008 by SGA Lists
|
|
|
|
0 items
